He runs Amperos Health, the New York startup whose AI biller, Amanda, spends her days on hold with insurance companies on behalf of dermatology clinics in all fifty states.
The story
The math is the pitch. A healthcare CFO told Michal Miernowski, some years back, that his clinic employed roughly one hundred doctors and three hundred people to collect the bills those doctors generated. This is either a joke about American healthcare or a business plan, and Miernowski, who had spent the years before at Ardea Partners, Onex and Goldman Sachs looking at healthcare services companies as an investor, decided it was a business plan.
Amperos Health is what he built. The company started in 2023 in New York, with Alvin Wu, formerly at Samsara and Fitbit, as chief product officer, and Wilson Wang, an early large-language-model engineer at Amazon, as CTO. Their flagship is called Amanda. Amanda is not a chatbot. Amanda is an AI biller that logs into insurance portals, dials payer call centers, refiles corrected claims, requests medical records, files appeals, and generally does the work that the three hundred humans used to do, only she does not stop at five p.m. and does not need a two-week onboarding.
"AI doesn't get tired, doesn't quit, and doesn't need to be retrained." This is a line Miernowski uses often. It is also, per the company's own materials, the first stated value at Amperos, which tells you something about the founder: the culture document opens by pointing out that the software does not have feelings. Read it as ruthless if you want. Read it as honest.
The pitch to hospitals is straightforward and, importantly, boring. Hand us your denied claims. We will handle the follow-up, the calls, the paperwork. You go back to being a clinic. Boring pitches are how you get to $700 million in annual recovered revenue across roughly 3,000 clinical sites in all fifty states, which is where Amperos is now. DOCS Dermatology, one of its customers, reports recovering 24% more claims without hiring a single additional biller. Bessemer Venture Partners led the $16 million Series A in April 2026, following a $4.2 million seed the prior June. Uncork Capital and Neo came along. Sofia Guerra at Bessemer described Amperos as "the first truly agentic AI platform we've seen to automate this workflow end-to-end," which is the kind of thing venture investors say and, occasionally, mean.
There is a small genre of founder in which someone spent five to eight years in private equity or investment banking and then decided the thing they had been evaluating from the outside was worth building from the inside. Miernowski is one of these. He studied economics, with a mathematical emphasis, and French at the University of Wisconsin-Madison from 2011 to 2015, worked at Goldman Sachs, moved to Onex to look at healthcare services investments, spent time at Ardea Partners, and, some time around 2023, walked out of the meeting rooms and into a New York startup office.
"I realized," he told AlleyWatch when Amperos raised its seed round in 2025, "that instead of discussing how we can serve more patients and provide more treatments, we were spending hours just trying to figure out how we can get enough cash in the door to pay staff and keep operating." Claims, he added, take so long to pay that a lot of clinics are forced to shut down or pull back services. The insurance denial rate in American healthcare is a real number and the collections shortfall it produces is roughly $26 billion. Amperos' seed pitch was that this was a software problem.
The design choice worth noting is that Amperos does not replace anything. Amanda lives inside the provider's existing billing system, which is how Miernowski describes it: "The AI that Amperos uses works directly within the provider's existing billing software, acting like a member of their team." Healthcare software procurement is, famously, an act of masochism, and any pitch that requires ripping out an EHR or an RCM system is a pitch that takes eighteen months to close and eight months to implement. Amperos avoids the whole thing.
The metrics the company publishes are the kind that get the attention of a CFO who has been staring at his aging AR report for six months. Claims are resolved five times faster than traditional approaches. Recovery per claim runs 20 to 22 percent higher than an outsourced vendor. Cost to collect drops by as much as half. Denial rates, over time, come down roughly 70 percent, because Amanda notices patterns and Amperos is starting to build the upstream layer that prevents denials in the first place. Miernowski's stated aspiration is to make Amperos the "AI-native infrastructure layer between providers and payers," which is a large-sounding phrase for what is, in practice, a piece of software that sits between the person who ordered the MRI and the person who is refusing to pay for it.
Numbers on the wall
Timeline
In their words
He is not a founder who fills the room. His public quotes are unusually plain. He tends to describe the product mechanically, name the pain point, and end the sentence. The advice he gives other founders is unglamorous in the same way.
Both quotes could be printed on a poster in any WeWork in Manhattan. What is unusual is that Miernowski appears to have actually run the company this way. Amperos in mid-2026 is a 30-person team with one product, one buyer profile, and a single obsession, which is why a Series A investor writes a check for it.
Human details
He studied French alongside economics at UW-Madison. He is not a computer science graduate turned founder. He is a liberal arts graduate turned investor turned founder.
Amperos' flagship AI has a proper name, Amanda, not a version number. This is deliberate; billing office staff have to trust it.
Miernowski's favorite spring day in New York involves Prospect Park's winding paths. His rainy-day answer is The Met.
Bessemer's Sofia Guerra, who led the Series A, called Amperos the first truly agentic AI platform Bessemer had seen automate the RCM workflow end-to-end.
The founding anecdote he uses is a ratio: 100 doctors to 300 collections staff at a single clinic he saw as an investor.
Amperos is HIPAA-compliant and SOC 2-attested, which sounds like paperwork and is, in this industry, a moat.
Questions people ask
He is the co-founder and CEO of Amperos Health, a New York-based startup building an AI-native denial management and revenue recovery platform for healthcare providers.
A healthcare technology company that automates insurance denial management and claims collections using agentic AI. Its flagship product, Amanda, is marketed as the first AI biller for healthcare denials.
Roughly $20.2M in total. That includes a $4.2M seed round in June 2025 and a $16M Series A in April 2026 led by Bessemer Venture Partners.
He worked in healthcare services investing and financial services, with prior roles at Goldman Sachs, Onex, and Ardea Partners. He studied economics and French at the University of Wisconsin-Madison.
Alvin Wu, chief product officer, previously at Samsara, Fitbit, and Backbone. Wilson Wang, CTO, an early LLM engineer at Amazon.
Where to go next